	US 12,144,853 B2
	Targeted vaccination in the liver
Sean C. Murphy, Seattle, WA (US); and Bradley C. Stone, Seattle, WA (US)
Assigned to UNIVERSITY OF WASHINGTON, Seattle, WA (US)
Filed by UNIVERSITY OF WASHINGTON, Seattle, WA (US)
Filed on Jan. 12, 2021, as Appl. No. 17/147,438.
Claims priority of provisional application 62/960,499, filed on Jan. 13, 2020.
Prior Publication US 2021/0236615 A1, Aug. 5, 2021
Int. Cl. A61K 39/015 (2006.01); A61K 39/00 (2006.01); A61P 33/06 (2006.01); C07K 14/445 (2006.01)

CPC A61K 39/015 (2013.01) [A61P 33/06 (2018.01); C07K 14/445 (2013.01); A61K 2039/52 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); Y02A 50/30 (2018.01)]

11 Claims

1. A trapping composition comprising:

a trapping antigenic component comprising a nucleic acid molecule encoding a Plasmodium protein or an antigenic fragment thereof;

a protective component comprising a nanoparticle; and

a liver cell-targeting component conjugated to the protective component to form a liver cell-targeting vehicle capable of delivering the trapping composition to a liver cell or liver tissue, wherein the liver cell-targeting vehicle comprises one or more bile acids conjugated to the nanoparticle to form a bile-acid conjugated nanoparticle.